CSF2RB
Basic information
Region (hg38): 22:36913628-36940439
Previous symbols: [ "IL3RB" ]
Links
Phenotypes
GenCC
Source:
- surfactant metabolism dysfunction, pulmonary, 5 (Moderate), mode of inheritance: AR
- hereditary pulmonary alveolar proteinosis (Supportive), mode of inheritance: AR
- surfactant metabolism dysfunction, pulmonary, 5 (Limited), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Surfactant metabolism dysfunction, pulmonary, 5 | AR | Pulmonary | The condition typically manifests with childhood-onset respiratory insufficiency (though adult-onset disease has also been reported) due to pulmonary alveolar proteinosis, and whole-lung lavage may be beneficial; It has been reported that diagnosis has important therapeutic implications, as BMT/HSCT can be effective | Pulmonary | 9410898; 21075760 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CSF2RB gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 153 | 11 | 170 | |||
missense | 319 | 333 | ||||
nonsense | 7 | |||||
start loss | 1 | |||||
frameshift | 10 | 10 | ||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 2 | |||||
splice region | 8 | 12 | 20 | |||
non coding | 64 | 38 | 102 | |||
Total | 0 | 1 | 345 | 226 | 55 |
Variants in CSF2RB
This is a list of pathogenic ClinVar variants found in the CSF2RB region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
22-36921806-T-C | Benign (Nov 10, 2018) | |||
22-36921872-C-T | Benign (Jun 10, 2019) | |||
22-36921928-A-G | Benign (Nov 10, 2018) | |||
22-36921972-G-T | Benign (Nov 10, 2018) | |||
22-36921991-C-T | Benign (Nov 27, 2018) | |||
22-36922079-T-G | Likely benign (May 26, 2019) | |||
22-36922133-C-T | Likely benign (Jun 10, 2019) | |||
22-36922208-A-T | Uncertain significance (Jun 09, 2022) | |||
22-36922215-T-A | Uncertain significance (Nov 10, 2022) | |||
22-36922224-G-T | Uncertain significance (Oct 14, 2023) | |||
22-36922235-A-G | Uncertain significance (Nov 03, 2023) | |||
22-36922243-G-A | Likely benign (Oct 04, 2022) | |||
22-36922263-G-A | Uncertain significance (Jan 05, 2023) | |||
22-36922264-C-T | Likely benign (Oct 07, 2023) | |||
22-36922267-C-A | CSF2RB-related disorder | Benign/Likely benign (Mar 01, 2024) | ||
22-36922275-G-C | Uncertain significance (Sep 05, 2023) | |||
22-36922276-G-A | Benign (Jan 29, 2024) | |||
22-36922287-A-G | Uncertain significance (Mar 10, 2023) | |||
22-36922292-C-T | Likely benign (Jun 10, 2022) | |||
22-36922293-G-A | Likely benign (Mar 02, 2023) | |||
22-36922297-C-T | Likely benign (Aug 06, 2022) | |||
22-36922384-C-T | Benign (Nov 10, 2018) | |||
22-36922404-G-A | Benign (Nov 10, 2018) | |||
22-36922437-G-A | Benign (Mar 24, 2019) | |||
22-36922473-T-C | Benign (Nov 10, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CSF2RB | protein_coding | protein_coding | ENST00000403662 | 13 | 26822 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.176 | 0.824 | 125268 | 2 | 478 | 125748 | 0.00191 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.129 | 518 | 526 | 0.984 | 0.0000325 | 5759 |
Missense in Polyphen | 77 | 96.251 | 0.79999 | 1260 | ||
Synonymous | -1.81 | 258 | 224 | 1.15 | 0.0000148 | 1901 |
Loss of Function | 4.00 | 8 | 32.7 | 0.245 | 0.00000161 | 342 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000904 | 0.000904 |
Ashkenazi Jewish | 0.0246 | 0.0247 |
East Asian | 0.000163 | 0.000163 |
Finnish | 0.00106 | 0.00106 |
European (Non-Finnish) | 0.00142 | 0.00142 |
Middle Eastern | 0.000163 | 0.000163 |
South Asian | 0.0000980 | 0.0000980 |
Other | 0.00228 | 0.00228 |
dbNSFP
Source:
- Function
- FUNCTION: High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor.;
- Disease
- DISEASE: Pulmonary surfactant metabolism dysfunction 5 (SMDP5) [MIM:614370]: A rare lung disorder due to impaired surfactant homeostasis. It is characterized by alveolar filling with floccular material that stains positive using the periodic acid- Schiff method and is derived from surfactant phospholipids and protein components. Excessive lipoproteins accumulation in the alveoli results in severe respiratory distress. {ECO:0000269|PubMed:21075760}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Jak-STAT signaling pathway - Homo sapiens (human);Pathways in cancer - Homo sapiens (human);Apoptosis - Homo sapiens (human);Cytokine-cytokine receptor interaction - Homo sapiens (human);IL-5 Signaling Pathway;IL-3 Signaling Pathway;Signaling by GPCR;IL-3 signaling;Signal Transduction;Signaling by Interleukins;regulation of bad phosphorylation;Cytokine Signaling in Immune system;JAK STAT MolecularVariation 1;Surfactant metabolism;Metabolism of proteins;il 3 signaling pathway;Immune System;Interleukin receptor SHC signaling;Interleukin-2 family signaling;IL5-mediated signaling events;KitReceptor;IL-5 signaling;JAK STAT MolecularVariation 2;RAF/MAP kinase cascade;MAPK1/MAPK3 signaling;MAPK family signaling cascades;JAK STAT pathway and regulation;IL3;IL5;G beta:gamma signalling through PI3Kgamma;G-protein beta:gamma signalling;GPCR downstream signalling;GMCSF-mediated signaling events;IL3-mediated signaling events;Interleukin-3, 5 and GM-CSF signaling
(Consensus)
Recessive Scores
- pRec
- 0.249
Intolerance Scores
- loftool
- 0.0832
- rvis_EVS
- -1.08
- rvis_percentile_EVS
- 7.32
Haploinsufficiency Scores
- pHI
- 0.311
- hipred
- N
- hipred_score
- 0.429
- ghis
- 0.535
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.698
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Csf2rb2
- Phenotype
- normal phenotype; hematopoietic system phenotype; respiratory system phenotype; immune system phenotype;
Gene ontology
- Biological process
- MAPK cascade;signal transduction;respiratory gaseous exchange;peptidyl-tyrosine phosphorylation;cytokine-mediated signaling pathway;response to lipopolysaccharide;cellular response to interleukin-3;interleukin-5-mediated signaling pathway;interleukin-3-mediated signaling pathway;cellular protein metabolic process
- Cellular component
- plasma membrane;integral component of plasma membrane;granulocyte macrophage colony-stimulating factor receptor complex
- Molecular function
- protein tyrosine kinase activity;interleukin-3 receptor activity;interleukin-5 receptor activity;Ras guanyl-nucleotide exchange factor activity;protein binding;signaling receptor activity